Compare Dr. Reddys with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 30.3 20.8 145.9% View Chart
P/BV x 3.5 2.3 152.5% View Chart
Dividend Yield % 0.7 0.7 96.2%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
CIPLA
Mar-19
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,875678 424.0%   
Low Rs1,888484 390.2%   
Sales per share (Unadj.) Rs930.2198.2 469.3%  
Earnings per share (Unadj.) Rs117.418.5 633.9%  
Cash flow per share (Unadj.) Rs185.835.0 530.9%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %0.80.5 162.6%  
Book value per share (Unadj.) Rs844.4186.3 453.2%  
Shares outstanding (eoy) m166.07805.70 20.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.9 87.4%   
Avg P/E ratio x20.331.4 64.7%  
P/CF ratio (eoy) x12.816.6 77.2%  
Price / Book Value ratio x2.83.1 90.5%  
Dividend payout %17.016.2 105.2%   
Avg Mkt Cap Rs m395,496468,031 84.5%   
No. of employees `00022.022.6 97.0%   
Total wages/salary Rs m33,56228,565 117.5%   
Avg. sales/employee Rs Th7,032.87,053.1 99.7%   
Avg. wages/employee Rs Th1,527.91,261.5 121.1%   
Avg. net profit/employee Rs Th887.7659.1 134.7%   
INCOME DATA
Net Sales Rs m154,482159,710 96.7%  
Other income Rs m3,3754,766 70.8%   
Total revenues Rs m157,857164,475 96.0%   
Gross profit Rs m31,78230,973 102.6%  
Depreciation Rs m11,34813,263 85.6%   
Interest Rs m8891,684 52.8%   
Profit before tax Rs m22,92020,791 110.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8585,695 67.7%   
Profit after tax Rs m19,50014,924 130.7%  
Gross profit margin %20.619.4 106.1%  
Effective tax rate %16.827.4 61.4%   
Net profit margin %12.69.3 135.1%  
BALANCE SHEET DATA
Current assets Rs m111,101124,266 89.4%   
Current liabilities Rs m58,97337,715 156.4%   
Net working cap to sales %33.754.2 62.3%  
Current ratio x1.93.3 57.2%  
Inventory Days Days7991 87.6%  
Debtors Days Days9495 99.3%  
Net fixed assets Rs m101,245105,190 96.2%   
Share capital Rs m8301,611 51.5%   
"Free" reserves Rs m139,406148,511 93.9%   
Net worth Rs m140,236150,123 93.4%   
Long term debt Rs m22,00038,301 57.4%   
Total assets Rs m224,656239,633 93.7%  
Interest coverage x26.813.3 200.7%   
Debt to equity ratio x0.20.3 61.5%  
Sales to assets ratio x0.70.7 103.2%   
Return on assets %9.16.9 130.9%  
Return on equity %13.99.9 139.9%  
Return on capital %14.911.8 126.3%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67357,410 154.5%   
Fx outflow Rs m19,10419,041 100.3%   
Net fx Rs m69,56938,368 181.3%   
CASH FLOW
From Operations Rs m28,70416,911 169.7%  
From Investments Rs m-7,727-16,687 46.3%  
From Financial Activity Rs m-21,326-3,487 611.6%  
Net Cashflow Rs m-314-3,451 9.1%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 1,375 Points; Nifty Ends Below 8,300 Mark(Closing)

Indian share markets witnessed selling pressure throughout the day and ended deep in the red with Sensex and Nifty witnessing a sharp fall during closing hours.

Related Views on News

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 30, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS